A Phase 1b Study to Evaluate the Safety of XEN-101

Summary

This Phase 1b study will evaluate the effects of XEN-101 in subjects with obesity

Timeline

Start

2024-05-24

Primary completion

2024-09-09

Completion

2024-09-09

Outcome

Outcome not reported

Stopped: “Study not stopped for safety reasons. Data were reviewed after the first 23 patients had completed scheduled dosing and there was no signal of efficacy for change in body weight. This clinical trial has been determined to be futile.”

Drugs

Indications